Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866431 | 0.95 | MCHR1 (0.44) | MEN1KMT2AMCHR1SLC6A3SSTR3 | |
| SCHEMBL7306485 | 0.90 | SLC6A3 (0.45) | MEN1KMT2AMCHR1SLC6A3TACR2 | |
| SCHEMBL7750691 | 0.84 | SLC6A3 (0.46) | MEN1KMT2AMCHR1SLC6A3SLC6A2 | |
| SCHEMBL7305694 | 0.83 | SLC6A3 (0.44) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7307778 | 0.83 | TACR2 (0.59) | TACR2 | |
| SCHEMBL8364709 | 0.82 | MEN1 (0.40) | MEN1KMT2AMCHR1ATMHPGD | |
| SCHEMBL9317353 | 0.81 | HPGD (0.43) | MCHR1SLC6A3HPGDSMN1; SMN2 | |
| SCHEMBL8782131 | 0.81 | SLC6A3 (0.42) | MCHR1SLC6A3 | |
| SCHEMBL8838798 | 0.80 | MCHR1 (0.40) | MCHR1SLC6A3HPGD | |
| SCHEMBL7305306 | 0.79 | SLC6A3 (0.41) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294537-B1 | NEUROKININS USED FOR TREATMENT OF DISEASES | SANOFI-SYNTHELABO (FR) | 2001-09-25 | — | — | US | disclosed |
| US-6124316-A | ACTIVE DRUG TREATING PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, OF HYPERTENSION AND, NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 2000-09-26 | — | — | US | disclosed |
| US-5942523-A | NOVEL PIPERIDINE DERIVATIVES WHOSE SPECIFIC STRUCTURE INCLUDES AT POSITION 1 AN ALKYL CHAIN HAVING A 3,4-DICHLOROPHENYL GROUP ATTACHED; HIGH SELECTIVITY TO THE NK3 RECEPTOR; UNIT DOSAGE FORM; TREATING PSYCHIATRIC DISEASES | SANOFI (FR) | 1999-08-24 | — | — | US | disclosed |
| US-5741910-A | PIPERIDINE DERIVATIVE INTERMEDIATES | SANOFI (FR) | 1998-04-21 | — | — | US | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |